Arcagy/ Gineco Group
Clinical trials sponsored by Arcagy/ Gineco Group, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New trial tests drug combo to keep ovarian cancer at bay Results expected Feb 2027 (estimated)
- Weekly chemo boost could help ovarian cancer patients who Don't respond to standard treatment Results expected Jun 2027 (estimated)
- New hope for rare, deadly gynecologic cancers: drug combo trial launches Results expected Jun 2027 (estimated)
-
When to operate? ovarian cancer trial tests best time for surgery after chemo
Disease control CompletedThis trial studied 211 women with advanced ovarian cancer who were not candidates for upfront surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing leads to longer disease-free survival. All patients re…
Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Immunotherapy combo shows promise in ovarian cancer trial
Disease control CompletedThis study tested two immunotherapy drugs, durvalumab and tremelimumab, given with chemotherapy before and after surgery for advanced ovarian cancer. The goal was to see if this combination is safe and feasible. About 69 women with stage IIIC to IV ovarian cancer took part. The r…
Phase 1/2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedThis phase II trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before surgery helps women with stage IV ovarian cancer. 91 participants received either chemo alone or chemo plus pembrolizumab, followed by surgery. The goal was t…
Phase 2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 26, 2026 15:25 UTC
-
Blood test score may guide ovarian cancer treatment decisions
Knowledge-focused CompletedThis study looks at whether a score called KELIM can predict how well ovarian cancer patients respond to maintenance treatment with PARP inhibitors after initial chemotherapy. Researchers will analyze data from 243 patients who took part in the PAOLA-1 trial. If KELIM proves usef…
Sponsor: ARCAGY/ GINECO GROUP • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Ovarian cancer genetics under the microscope: no treatment, just knowledge
Knowledge-focused CompletedThis study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how the disease progresses. Researchers collected tumor samples and medical data to find links between DNA abnormalities and outcomes …
Sponsor: ARCAGY/ GINECO GROUP • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC